RecruitingNot ApplicableNCT06933381
Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
Topical Vapocoolant to Reduce Pain With Nexplanon Insertion: A Randomized Controlled Trial
Sponsor
Queen's Medical Center
Enrollment
70 participants
Start Date
Jun 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
Eligibility
Sex: FEMALEMin Age: 14 Years
Inclusion Criteria4
- At least 14 years or older
- Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402
- English speaking
- Able and willing to sign the informed consent form and agree to terms of the study
Exclusion Criteria5
- Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure
- Known previous exposure to vapocoolant spray
- Nexplanon removal and reinsertion same day during visit in the same arm
- Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane)
- Unable to provide written, informed consent in English
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEVapocoolant spray
Pain Ease will be used per manufacturer instruction, applying the spray for 5 seconds or until the skin turns white, whichever occurs first.
OTHERPlacebo
Nature's Tears will be applied to the arm as a placebo spray
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06933381